Aclarion Announces Publication of Nociscan Article in Special Pain Issue of the International Journal of Spine Surgery (IJSS)

Rhea-AI Summary

Aclarion (Nasdaq: ACON) announced publication of a featured Tech Update on its Nociscan solution in the Special Pain Issue of the International Journal of Spine Surgery (IJSS) on Dec 4, 2025. The article highlights a clinical case where a 27-year-old with chronic low back pain had MRI-suspected L4/5 and L5/S1 pathology; a four-level Nociscan exam detected biomarkers at L5/S1 only, guiding the surgeon to perform a single-level artificial disc replacement at L5/S1 that eliminated the patient’s pain and restored activity. The release emphasizes Nociscan as a noninvasive, evidence-supported SaaS platform for distinguishing painful versus nonpainful lumbar discs and notes IJSS’s role in disseminating spine care innovations to an international audience.

Positive

• Peer-reviewed publication in IJSS Special Pain Issue (Dec 4, 2025)
• Case-guided surgery limited to L5/S1, avoiding a wider procedure
• Clinical outcome reported: elimination of patient’s pain and return to activity
• Nociscan described as noninvasive SaaS to distinguish painful vs nonpainful discs
• Global relevance: references 266 million people with chronic low back pain

Negative

• Evidence limited to a single highlighted case example in the article

Key Figures

Chronic low back pain population 266 million people Estimated worldwide population targeted by Nociscan

Patient age 27 years old Case study patient in IJSS Nociscan article

Nociscan exam levels 4 levels Four-level Nociscan exam used in highlighted case

IJSS annual articles 150+ articles Articles published annually by IJSS from 40+ nations

Q3 2025 revenue $18,942 Quarterly revenue vs $14,407 a year earlier

Q3 2025 net loss $1.71 million Net loss for Q3 2025, higher than prior-year $1.37M

Cash and equivalents $11.34 million Cash balance at Q3 2025 after capital raises

October 2025 raise $2.5 million Additional capital raised in October 2025

Market Reality Check

$0.0398 Last Close

Volume Volume 135,697 is about 2.6x the 20-day average of 52,248 shares. high

Technical Price at $6.11 is trading below the 200-day MA of $12.57 and far under the $3,499.51 52-week high.

Peers on Argus 1 Up

ACON’s move contrasted with mixed peers: WORX -5.24%, VSEE -1.03%, DRIO +1.55%, while scanner activity only flagged BEAT at +5.19% without news, pointing to a stock-specific reaction.

Common Catalyst Several digital health peers (e.g., VSEE, DRIO) also had publication/innovation-focused news, suggesting a broader emphasis on data-driven care, but price moves were modest versus ACON.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 04	Journal publication	Positive	+5.0%	Featured IJSS article showcasing Nociscan-guided surgery case with pain resolution.
Dec 02	Leadership hire	Positive	+10.3%	Eastern U.S. Commercial Director appointment to drive Nociscan adoption and payer outreach.
Nov 05	Leadership hire	Positive	+0.0%	UK Commercial Director hire supporting reimbursed Nociscan rollout and early clinic use.
Oct 22	Industry award	Positive	-4.7%	Rising Star award for Nociscan clinical diagnostic technology at a digital health event.
Oct 14	Corporate update	Positive	-7.6%	Corporate update on scan growth, cash position, and CLARITY trial progress.

Pattern Detected

Recent ACON news often produced sharp but inconsistent reactions: commercial and publication updates sometimes aligned with gains, while seemingly positive corporate and award news previously saw negative or flat moves.

Recent Company History

Over the last few months, Aclarion highlighted multiple milestones around its Nociscan platform. A corporate update on Oct 14, 2025 detailed record scan growth and strong cash but coincided with a -7.64% move. A digital health award on Oct 22 saw shares down 4.72%. Subsequent commercial hires in the UK and Eastern U.S. showed expansion efforts, with the Dec 2 appointment linked to a 10.31% gain. Today’s IJSS Special Pain Issue article continues the evidence and visibility theme and previously aligned with a 5.02% rise.

Market Pulse Summary

This announcement adds peer-reviewed validation and a detailed case example for Nociscan, underscoring its role in distinguishing painful from nonpainful lumbar discs for an estimated 266 million chronic low back pain sufferers. It builds on earlier commercial hires and award recognition to expand awareness among spine specialists. At the same time, recent filings show ongoing net losses despite growing revenue, so investors may watch for future data from the CLARITY trial, additional reimbursement wins, and further adoption indicators.

Key Terms

biomarkers medical

"leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians"

Biomarkers are measurable indicators found in the body, such as substances in blood or tissues, that reveal information about health or disease. For investors, they can signal how well a medical treatment is working or whether a disease is developing, helping to assess the potential success or risks of healthcare companies or innovations. Think of biomarkers as biological signals that provide clues about a person’s health status.

augmented intelligence technical

"proprietary augmented intelligence (AI) algorithms to help physicians identify"

Augmented intelligence combines human skills with advanced technology to enhance decision-making and problem-solving. It acts like a helpful partner that provides insights and suggestions, allowing people to make better choices more quickly. For investors, this means smarter analysis, improved efficiency, and the ability to respond to market changes with greater confidence.

ICD-10 medical

"increasingly granular ICD-10 classifications emerge—including pre-MRS tools"

ICD-10 is the international system used to assign standardized alphanumeric codes to diseases, symptoms, procedures and causes of death, acting like a common medical language or barcode catalog for health conditions. Investors care because those codes drive billing, reimbursement, regulatory reporting and health data trends, so changes in coding practice or code sets can shift revenue flows, demand for treatments and perceived market risk for healthcare-related companies.

MR Spectroscopy (MRS) medical

"giving physicians new insights extracted from MR Spectroscopy (MRS) to better understand"

Magnetic resonance spectroscopy (MRS) is a technique that uses magnetic fields and radio waves to analyze the chemical composition of tissues or materials. It provides detailed information about the presence and concentration of specific substances, much like a specialized scanner that reveals the chemical makeup of an object. Investors care because advancements in MRS can lead to better medical diagnostics and treatments, potentially influencing healthcare markets and technological innovation.

artificial disc replacement medical

"to limit the surgical intervention to an artificial disc replacement at only the L5/S1 disc"

Artificial disc replacement is a surgical procedure that involves removing a damaged or worn-out spinal disc and replacing it with a synthetic device designed to mimic the function of a natural disc. This procedure can help restore mobility and reduce pain in the spine. For investors, advancements or changes in this technology can impact medical device companies and healthcare markets, reflecting broader trends in healthcare innovation.

SaaS platform technical

"Nociscan solution is the first evidence-supported SaaS platform to noninvasively help physicians"

A SaaS platform is software delivered over the internet that customers access through a subscription instead of installing and running it on their own computers; the provider hosts, updates, and secures the application remotely. Investors care because SaaS businesses often generate predictable, recurring revenue and can scale quickly as more customers sign up, making them easier to value and potentially more profitable over time—similar to a utility that collects steady fees as its user base grows.

AI-generated analysis. Not financial advice.

• Featured article strengthens growing body of clinical evidence for Nociscan by highlighting a successful case study
  
• Special Pain issue features breakthrough innovations shaping the future of spine care
• IJSS publishes over 150 articles annually representing 40+ nations
  

BROOMFIELD, Colo., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today the publication of a featured article Tech Update, sponsored by Aclarion, in the upcoming Special Pain Issue of the International Journal of Spine Surgery (IJSS).

“The Special Pain Issue of IJSS highlights a simple truth: pain is not just a symptom—it is a complex neurobiological, psychological, and existential condition,” said Morgan P. Lorio, MD, FACS, Guest Editor. “As more granular diagnostics and increasingly granular ICD-10 classifications emerge—including pre-MRS tools capable of identifying the pain generator—clinicians are gaining new ways to ‘see’ pain that were previously inaccessible. This edition brings together innovations that integrate objective biomarkers with clinical judgment and ultimately improve how we diagnose, treat, and prevent suffering. IJSS is publishing this issue now because the field is at an inflection point, and our patients deserve nothing less than a more complete, science-driven understanding of pain.”

Aclarion’s Nociscan solution is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine for the estimated 266 million people who suffer from chronic low back pain worldwide.

In the case example highlighted, a 27-year-old patient with chronic low back pain initially underwent an MRI of the lumbar spine which visually suggested the L4/5 and L5/S1 disc levels were likely the source of this patient’s pain. The treating surgeon subsequently ordered a four-level Nociscan exam to gather more information. Nociscan revealed pain biomarkers for the L5/S1 disc but not for the L4/5 disc. The surgeon utilized this information in conjunction with the MRI data and the patient’s overall clinical history to limit the surgical intervention to an artificial disc replacement at only the L5/S1 disc resulting in the elimination of the patient’s pain and full return to an active lifestyle.

“We are pleased that the Nociscan Tech Update is featured in the Special Pain Issue of such a high caliber journal like IJSS,” said Ryan Bond, Chief Strategy Officer at Aclarion. “The journal has long been a leader among its peers for advancing scientific and clinical excellence in spine care. The Special Pain Issue is emblematic of its commitment to enhancing the science and practice of non-operative and surgical interventions to restore and improve function to the spine. Likewise, at Aclarion, we are dedicated to giving physicians new insights extracted from MR Spectroscopy (MRS) to better understand a patient’s pain and differentiate between pathological pain and physiological aging.”

IJSS is a prominent peer-reviewed journal and the Special Pain Issue highlights innovations that are shaping the future of spine care. The IJSS is dedicated to educating spine surgeons worldwide by reporting on the scientific basis, indications, surgical techniques, complications, outcomes, and follow-up data for promising spinal procedures. Additionally, the IJSS periodically publishes supplements, referred to as Special Issues, like the Pain Issue, to provide focused insights on high-impact areas of clinical need and innovation.

To read the advance online publication, follow this link.

To find a Nociscan center, view our site map here.

For more information on Nociscan, please email: info@aclarion.com

All organizations cited and/or quotes from individuals not part of Aclarion have reviewed and approved the contents herein.

About Aclarion, Inc.

Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes,” “will” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. Forward-looking statements in this release include, among others, statements regarding the potential benefits of our Nociscan technology, and the Company’s plans for future regulatory and commercialization activities. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contacts:

Kirin M. Smith
PCG Advisory, Inc.
ksmith@pcgadvisory.com

Media Contacts:

Jessica Starman
media@elev8newmedia.com

FAQ

What did Aclarion (ACON) announce on Dec 4, 2025 about Nociscan?

Aclarion announced a featured Tech Update on Nociscan published in the IJSS Special Pain Issue on Dec 4, 2025.

How did Nociscan affect surgical decision-making in the published case?

A four-level Nociscan exam identified biomarkers only at L5/S1, guiding a single-level artificial disc replacement and eliminating the patient’s pain.

Is Nociscan invasive and what does it detect for ACON?

Nociscan is described as a noninvasive SaaS platform that helps distinguish painful from nonpainful lumbar discs using biomarkers.

Which journal published Aclarion’s Nociscan Tech Update and why is it notable?

The International Journal of Spine Surgery (IJSS) published the Tech Update in its Special Pain Issue, highlighting innovations in spine diagnostics and care.

What clinical result was reported for the patient in the Nociscan case study?

The patient experienced elimination of pain and a full return to an active lifestyle after targeted L5/S1 intervention.

How widespread is the potential need for lumbar pain diagnostics referenced by Aclarion?

The announcement cites an estimated 266 million people worldwide who suffer from chronic low back pain.